FDA hears pros and cons of BTC in hearing

Share this article:

FDA heard conflicting opinions on the wisdom of creating a “behind-the-counter” drug class at a Washington hearing Wednesday.

The agency declined to set a deadline for a decision on the matter, for which it is soliciting public comment through Nov. 28. “Our timetable depends on what conclusions we reach internally, based on public comments received today and which might come into the docket,” said FDA deputy commissioner for public policy Randall Lutter, who added that FDA will soon make some “next steps” public.

Pharmacists love the idea, which would make them the mediators of a new class of drugs more restricted than OTC but requiring their sign-off instead of a physician's. Doctors, fearing an erosion of their authority and their ability to monitor treatment, aren't so hot on it. “When a drug product is considered unsafe without supervision, a physician should be responsible for supervising the use of that drug,” said Dr. Joseph Cranston, director of science, research and technology for the American Medical Association (AMA). “There is little scientific evidence to support the need for a third class of drugs, and many questions about the impact of this class remain unanswered. The AMA is concerned that a third class of drugs could have a negative impact on patient access to some drugs, reflect an increase in costs and potentially harm patients.”

Perhaps reflecting ambiguity toward the move among its member companies, Pharmaceutical Research and Manufacturers of America (PhRMA) declined to take a strong stance on the issue one way or another. “PhRMA has not been involved in issues related to over-the-counter or behind-the-counter switches,” said PhRMA SVP Ken Johnson. “However, we believe that pharmaceutical research companies themselves are in the best position to examine the safety profile of any medicine that a company is considering for OTC or behind-the-counter status."

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...